As a fifth of adults in the UK have diabetes or pre-diabetes, the politics of physical activity policy must be tackled, argue Karen Milton and colleagues Recent data show that one in five adults in ...

Type 2 diabetes is a global health challenge affecting more than 400 million adults. While it is often seen as a lifelong ...

After years of uncertainty the NHS is on the brink of a data sharing agreement that will open up valuable data to researchers. Stephen Armstrong reports The BMJ understands that NHS England will allow ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

Obesity strategy should not be built around a single drug Tirzepatide (Mounjaro) has had a remarkable journey to prominence since its UK marketing authorisation in 2023.1 Approved for glycaemic ...

Researchers said further trials were needed to confirm the findings, which have been published in the BMJ. Diabetes UK estimates that about 4.4 million people in the UK are living with a diabetes ...

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...

Workplace culture plays an integral role in the successful adoption of lifestyle medicine programming within health systems, ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...